HRP20161380T1 - Farmaceutski sastavi za zamjensku terapiju glukokortikoidima - Google Patents

Farmaceutski sastavi za zamjensku terapiju glukokortikoidima Download PDF

Info

Publication number
HRP20161380T1
HRP20161380T1 HRP20161380TT HRP20161380T HRP20161380T1 HR P20161380 T1 HRP20161380 T1 HR P20161380T1 HR P20161380T T HRP20161380T T HR P20161380TT HR P20161380 T HRP20161380 T HR P20161380T HR P20161380 T1 HRP20161380 T1 HR P20161380T1
Authority
HR
Croatia
Prior art keywords
hydrocortisone
tablet
dosage form
use according
immediate release
Prior art date
Application number
HRP20161380TT
Other languages
English (en)
Croatian (hr)
Inventor
Stanko Skrtic
Jörgen JOHNSSON
Hans Lennernäs
Thomas Hedner
Gudmundur Johannsson
Original Assignee
Shire Viropharma Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Viropharma Incorporated filed Critical Shire Viropharma Incorporated
Publication of HRP20161380T1 publication Critical patent/HRP20161380T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
HRP20161380TT 2004-04-22 2005-04-21 Farmaceutski sastavi za zamjensku terapiju glukokortikoidima HRP20161380T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US56420504P 2004-04-22 2004-04-22
SE0401031A SE0401031D0 (sv) 2004-04-22 2004-04-22 A new glucocorticoid replacement therapy
PCT/EP2005/004400 WO2005102271A2 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy
EP05735076.1A EP1744730B1 (en) 2004-04-22 2005-04-21 Pharmaceutical compositions for glucocorticoid replacement therapy

Publications (1)

Publication Number Publication Date
HRP20161380T1 true HRP20161380T1 (hr) 2016-12-02

Family

ID=35197481

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20161380TT HRP20161380T1 (hr) 2004-04-22 2005-04-21 Farmaceutski sastavi za zamjensku terapiju glukokortikoidima
HRP20210348TT HRP20210348T1 (hr) 2004-04-22 2021-03-01 Farmaceutski sastavi za terapiju zamjene glukokortikoida

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20210348TT HRP20210348T1 (hr) 2004-04-22 2021-03-01 Farmaceutski sastavi za terapiju zamjene glukokortikoida

Country Status (25)

Country Link
US (3) US8425937B2 (enExample)
EP (2) EP1744730B1 (enExample)
JP (2) JP5149618B2 (enExample)
CN (2) CN1942176B (enExample)
AU (1) AU2005235370B2 (enExample)
BR (1) BRPI0510044B8 (enExample)
CA (1) CA2564000C (enExample)
CY (2) CY1118275T1 (enExample)
DK (2) DK3072507T3 (enExample)
ES (2) ES2600556T3 (enExample)
HR (2) HRP20161380T1 (enExample)
HU (2) HUE030546T2 (enExample)
IL (2) IL178776A (enExample)
LT (2) LT3072507T (enExample)
ME (1) ME02584B (enExample)
MX (2) MXPA06012011A (enExample)
NZ (1) NZ585340A (enExample)
PL (2) PL3072507T3 (enExample)
PT (2) PT3072507T (enExample)
RS (2) RS61501B1 (enExample)
SE (1) SE0401031D0 (enExample)
SG (1) SG188081A1 (enExample)
SI (1) SI3072507T1 (enExample)
WO (1) WO2005102271A2 (enExample)
ZA (1) ZA200609680B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
PL1744760T3 (pl) * 2004-04-22 2015-04-30 Acucort Ab Kompozycja farmaceutyczna do ostrego leczenia glikokortykosteroidami
EP1971312A1 (en) * 2005-12-06 2008-09-24 MonoSol Rx LLC Topical film compositions for delivery of actives
FR2926722B1 (fr) * 2008-01-25 2010-09-03 Substipharm Dev Formulation pharmaceutique appropriee pour la preparation de comprimes orodispersibles de prednisolone
EP2151235B1 (de) * 2008-07-21 2011-02-16 Dr. Falk Pharma Gmbh Pharmazeutische Formulierung zur Behandlung des oberen Verdauungstraktes
US20120183610A1 (en) * 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
MX337429B (es) * 2010-05-20 2016-03-04 Duocort Pharma Ab Posologia y administracion de composiciones basadas en glucocortticoides.
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
GB201202433D0 (en) * 2012-02-13 2012-03-28 Diurnal Ltd Controlled drug release
JP2014086673A (ja) 2012-10-26 2014-05-12 Mitsubishi Electric Corp モノリシック集積回路
HUE056810T2 (hu) 2012-11-02 2022-03-28 Murray & Poole Entpr Ltd Szív- és érrendszeri események kezelése és megelõzése kolchicin alkalmazásával
HRP20210963T1 (hr) * 2013-04-16 2021-09-17 Murray & Poole Enterprises, Ltd. Formulacija za kontinuirano otpuštanje kolhicina i postupci priprave istog
BR112015026418B1 (pt) 2013-04-16 2022-10-04 Murray And Poole Enterprises Limited Formulação de liberação prolongada de colchicina e uso da referida formulação de liberação prolongada de colchicina
GB201308933D0 (en) * 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
MX348595B (es) * 2013-08-02 2017-06-21 Laboratorio Raam De Sahuayo S A De C V Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
EP2886108B2 (de) 2013-12-23 2022-11-02 Dr. Falk Pharma Gmbh Optimierte pharmazeutische Formulierung zur Behandlung von entzündlichen Veränderungen des Ösophagus
ES2906778T3 (es) * 2015-03-30 2022-04-20 Corcept Therapeutics Inc Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
RU2748437C2 (ru) * 2019-10-28 2021-05-25 Федеральное государственное бюджетное учреждение науки Институт цитологии Российской академии наук (ИНЦ РАН) Производное гидрокортизона в качестве средства для лечения болезни Альцгеймера
FR3116439B1 (fr) * 2020-11-26 2023-08-04 Laboratoire Dielen Comprimé pelliculé contenant au moins un principe actif, adapté à l’administration par voie orale dudit au moins un principe actif chez des sujets humains

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2260384C3 (de) * 1972-12-09 1979-11-29 Hoechst Ag, 6000 Frankfurt Oral zu applizierendes Corticosteroid-Präparat
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5314697A (en) 1992-10-23 1994-05-24 Schering Corporation Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
PT745382E (pt) * 1994-01-31 2004-04-30 Yamanouchi Pharma Co Ltd Forma moldada por compressao com solubilidade intra-oral e processo para a sua producao
US5534263A (en) 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
DE19718012C1 (de) * 1997-04-29 1998-10-08 Jenapharm Gmbh Verfahren zur Herstellung peroral anwendbarer fester Arzneiformen mit gesteuerter Wirkstoffabgabe
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
US6500459B1 (en) 1999-07-21 2002-12-31 Harinderpal Chhabra Controlled onset and sustained release dosage forms and the preparation thereof
US6156743A (en) 1999-10-18 2000-12-05 Whitcomb; John E. Method of decreasing fatigue
AR026148A1 (es) * 2000-01-21 2003-01-29 Osmotica Argentina S A Dispositivo osmotico con pasaje preformado que aumenta de tamano
EP1368000A4 (en) 2001-03-13 2004-12-01 Penwest Pharmaceuticals Co CHRONOTHERAPEUTIC PHARMACEUTICAL FORMS CONTAINING A GLUCOCORTICOSTEROID
CA2441007C (en) * 2001-03-15 2009-06-09 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
PL372290A1 (en) 2002-02-07 2005-07-11 Pharmacia Corporation Pharmaceutical dosage form for mucosal delivery
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
PL1744760T3 (pl) 2004-04-22 2015-04-30 Acucort Ab Kompozycja farmaceutyczna do ostrego leczenia glikokortykosteroidami
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
GB0623740D0 (en) 2006-11-28 2007-01-10 Diurnal Ltd Treatment of disease
US20120183610A1 (en) 2009-04-07 2012-07-19 Lennernaes Hans glucocorticoid therapy
MX337429B (es) 2010-05-20 2016-03-04 Duocort Pharma Ab Posologia y administracion de composiciones basadas en glucocortticoides.

Also Published As

Publication number Publication date
MXPA06012011A (es) 2007-04-16
AU2005235370B2 (en) 2011-06-09
US20080187586A1 (en) 2008-08-07
EP1744730A2 (en) 2007-01-24
JP5681679B2 (ja) 2015-03-11
BRPI0510044A (pt) 2007-10-16
JP2007533698A (ja) 2007-11-22
ES2857600T3 (es) 2021-09-29
WO2005102271A2 (en) 2005-11-03
SG188081A1 (en) 2013-03-28
US8425937B2 (en) 2013-04-23
MX344197B (es) 2016-12-08
AU2005235370A1 (en) 2005-11-03
CY1118275T1 (el) 2017-06-28
CN103006592B (zh) 2016-03-02
ME02584B (me) 2017-06-20
JP2012236846A (ja) 2012-12-06
HRP20210348T1 (hr) 2021-04-16
IL227375A (en) 2017-08-31
BRPI0510044B1 (pt) 2019-01-29
IL178776A0 (en) 2007-02-11
DK3072507T3 (da) 2021-02-08
HK1179525A1 (zh) 2013-10-04
BRPI0510044B8 (pt) 2021-05-25
HUE053248T2 (hu) 2021-06-28
EP3072507A1 (en) 2016-09-28
WO2005102271A3 (en) 2006-08-03
CN103006592A (zh) 2013-04-03
CY1124074T1 (el) 2022-03-24
PT3072507T (pt) 2021-02-23
HUE030546T2 (en) 2017-05-29
EP3072507B1 (en) 2020-12-23
PL1744730T3 (pl) 2017-01-31
PT1744730T (pt) 2016-10-07
LT3072507T (lt) 2021-02-25
EP1744730B1 (en) 2016-08-03
ZA200609680B (en) 2008-08-27
NZ585340A (en) 2012-04-27
RS61501B1 (sr) 2021-03-31
CN1942176A (zh) 2007-04-04
US10583146B2 (en) 2020-03-10
RS55198B1 (sr) 2017-01-31
CA2564000A1 (en) 2005-11-03
SI3072507T1 (sl) 2021-04-30
DK1744730T3 (en) 2016-08-29
CA2564000C (en) 2013-07-02
CN1942176B (zh) 2013-09-18
US20140242167A1 (en) 2014-08-28
LT1744730T (lt) 2016-10-25
US20130129823A1 (en) 2013-05-23
IL178776A (en) 2013-10-31
JP5149618B2 (ja) 2013-02-20
PL3072507T3 (pl) 2021-07-19
ES2600556T3 (es) 2017-02-09
SE0401031D0 (sv) 2004-04-22

Similar Documents

Publication Publication Date Title
HRP20161380T1 (hr) Farmaceutski sastavi za zamjensku terapiju glukokortikoidima
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
HRP20050077B1 (hr) Postupci i oblici doziranja za kontrolirano oslobađanje paliperidona
JP2008044951A5 (enExample)
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
WO2011107855A3 (en) Sustained release oral liquid suspension dosage form
HRP20231142T3 (hr) Kontrolirano oslobađanje 25-hidroksivitamina d
JP2007536311A5 (enExample)
JP2009530385A5 (ja) うつ病の治療のためのケタミンの投与
IL203747A (en) Use of a steroid sex precursor in the manufacture of a 13mg dose or less for daily dosing through the vagina to treat vaginal diseases and a vaginal pharmacological preparation containing it
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2009525985A5 (enExample)
HRP20220929T3 (hr) Sastav za inhalaciju koji sadrži aklidinij za liječenje astme
AU2012284627A8 (en) Method for manufacturing a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone and use thereof in the regression of chronic renal insufficiency, breast capsular contracture and hepatic fibrosis in humans
AR031978A1 (es) Formas de dosificacion de liberacion sostenida, el uso de las mismas para la manufactura de un medicamento para proporcionar efectiva terapia de reboxetina con dosificacion de una vez al dia y una composicion
Tuite et al. Recent developments in the pharmacological treatment of Parkinson’s disease
CN101574328B (zh) 一种唑吡坦盐的择时脉冲释药微丸
JP2018507243A5 (enExample)
EA200802350A3 (ru) Система доставки лекарств
AR056824A1 (es) Tableta de neramexano con matriz de liberacion modificada
IL320452A (en) Combination therapy for prostate cancer
JP2013516493A5 (enExample)
CA2570474A1 (en) A combination composition comprising paracetamol and ibuprofen
RS52672B2 (sr) Tretman reumatoidnih bolesti glukokortikoidom sa odloženim-oslobađanjem
ZA200106739B (en) Corticosteroid formulation.